Can psilocybin help you quit smoking?

December 17, 2021

Posted By: Morgan Kervitsky

Why We’re Bullish on MYCO-001, 99% Psilocybin, to Treat Nicotine Dependance

We have partnered with Dr. Matthew Johnson and Johns Hopkins University to advance our lead drug candidate MYCO-001 as a smoking cessation treatment. Our seamless phase 2/3 smoking cessation clinical trial, set to launch in early 2022, builds from Dr. Johnson’s previous research with Johns Hopkins University.

Positive Clinical Data Assessing Psilocybin for Smoking Cessation

2016 Smoking Cessation Study

  • Matthew Johnson
  • 15 participants
    • Psilocybin + cognitive behavioral therapy (CBT)
  • 67% abstinence from smoking at 12 months

2020 Smoking Cessation Study

  • Matthew Johnson
  • 100 participants
    • Psilocybin + CBT or the nicotine patch + CBT
  • Single dose of psilocybin
  • 12 Month follow-up
    • psilocybin treatment - 59% abstinence from smoking
    • nicotine patch - 28% abstinence from smoking

The Problem

In the U.S. alone, one in five deaths (or 1300 deaths a day) are caused by tobacco. Smoking cigarettes is an extremely tough habit to kick due to nicotine’s addictive nature and lack of safe and effective treatment options.

Unlike alcohol or opioid addiction, people addicted to nicotine tend to lead seemingly normal lives. Smoking cigarettes doesn’t usually cause a person to lose their job, home, or family and friends and today’s available treatment options come with many side effects like depression, weight gain, trouble sleeping, the list goes on. For these reasons, it can be difficult for smokers to find the motivation to make the switch to a healthier lifestyle.

“When administered after careful preparation and in a therapeutic context, psilocybin can lead to deep reflection about one’s life and spark motivation to change,” says Matthew Johnson, Ph.D.

Market Opportunity

With almost 6 million tobacco-related deaths per year worldwide, and that number projected to rise to an estimated 8 million annual mortalities by 2030, smoking cigarettes remains among the leading public health concerns of the 21st century.

Chantix, a blockbuster anti-smoking product, which reached $1.1 Billion in sales in 2019, was recalled earlier this year for its potential cancer risk leaving a large market opportunity.

The global smoking cessation market is expected to reach $64 Billion by 2026.

The Solution - MYCO-001 (99% pure psilocybin)

Dr. Johnson will be leading two clinical trials next year testing the safety and efficacy of MYCO-001 to treat nicotine dependence.

Mydecine’s Seamless Phase 2/3 Smoking Cessation Clinical Trial with Johns Hopkins Universtiy

Multi-Site NIDA Grant-Funded Smoking Cessation Study 

**1st government funded study to research psychedelics in over 50 years!

To date, Mydecine is the only company sponsoring clinical trials utilizing psilocybin to treat nicotine dependence!

With our lead drug candidate MYCO-001 in two clinical trials next year, Mydecine is positioned to bring a safer more effective treatment to market as early as 2024!

**For more information on the safety of psilocybin, check out this study published in the Journal of Psychopharmacology.